Trial record 1 of 1 for:
THRIVE-AA2
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) (THRIVE-AA2)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04797650 |
Recruitment Status :
Completed
First Posted : March 15, 2021
Results First Posted : July 3, 2023
Last Update Posted : July 3, 2023
|
Sponsor:
Concert Pharmaceuticals
Information provided by (Responsible Party):
Concert Pharmaceuticals
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment |
Condition |
Alopecia Areata |
Interventions |
Drug: CTP-543 matching placebo Drug: CTP-543 |
Enrollment | 517 |
Participant Flow
Recruitment Details | Participants were enrolled at study centers in Canada, France, Germany, Hungary, Poland, Spain and the United States from 10 June 2021 to 29 June 2022. |
Pre-assignment Details | 671 participants were screened, out of which 517 participants who experienced moderate to severe hair loss due to alopecia areata were enrolled to receive CTP-543 or placebo. |
Arm/Group Title | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
---|---|---|---|
Arm/Group Description | Participants received CTP-543 matched placebo tablets, orally, twice daily (BID) for up to 24 weeks. | Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks. | Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks. |
Period Title: Overall Study | |||
Started | 130 | 258 | 129 |
Efficacy Population [1] | 127 | 249 | 127 |
Safety Population [2] | 130 | 256 | 129 |
Completed | 119 | 233 | 120 |
Not Completed | 11 | 25 | 9 |
Reason Not Completed | |||
Reason Not Specified | 5 | 12 | 5 |
Treatment Emergent or Worsening Adverse Event | 1 | 7 | 0 |
Lack of Efficacy | 1 | 0 | 1 |
Non-compliance with Study Drug | 0 | 0 | 2 |
Lost to Follow-up | 4 | 6 | 1 |
[1]
Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period.
[2]
Safety population included all participants who received study drug during the treatment period
|
Baseline Characteristics
Arm/Group Title | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID | Total | |
---|---|---|---|---|---|
Arm/Group Description | Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks. | Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks. | Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks. | Total of all reporting groups | |
Overall Number of Baseline Participants | 130 | 258 | 129 | 517 | |
Baseline Analysis Population Description |
All randomized participants included all participants who were randomized in the study.
|
||||
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
|||||
Number Analyzed | 130 participants | 258 participants | 129 participants | 517 participants | |
39.7 (12.49) | 38.4 (12.30) | 39.7 (12.90) | 39.0 (12.49) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
|||||
Number Analyzed | 130 participants | 258 participants | 129 participants | 517 participants | |
Female |
88 67.7%
|
177 68.6%
|
84 65.1%
|
349 67.5%
|
|
Male |
42 32.3%
|
81 31.4%
|
45 34.9%
|
168 32.5%
|
|
Ethnicity (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
|||||
Number Analyzed | 130 participants | 258 participants | 129 participants | 517 participants | |
Hispanic or Latino |
11 8.5%
|
23 8.9%
|
9 7.0%
|
43 8.3%
|
|
Not Hispanic or Latino |
108 83.1%
|
205 79.5%
|
111 86.0%
|
424 82.0%
|
|
Unknown or Not Reported |
11 8.5%
|
30 11.6%
|
9 7.0%
|
50 9.7%
|
|
Race/Ethnicity, Customized
Measure Type: Count of Participants Unit of measure: Participants |
|||||
Race | Number Analyzed | 130 participants | 258 participants | 129 participants | 517 participants |
American Indian or Alaska Native |
1 0.8%
|
5 1.9%
|
0 0.0%
|
6 1.2%
|
|
Asian |
7 5.4%
|
4 1.6%
|
4 3.1%
|
15 2.9%
|
|
Black or African American |
10 7.7%
|
17 6.6%
|
7 5.4%
|
34 6.6%
|
|
White |
100 76.9%
|
203 78.7%
|
109 84.5%
|
412 79.7%
|
|
Other |
1 0.8%
|
1 0.4%
|
0 0.0%
|
2 0.4%
|
|
Not reported |
11 8.5%
|
28 10.9%
|
9 7.0%
|
48 9.3%
|
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts
the PI's rights to discuss or publish trial results after the trial is completed.
If an Investigator wants to publish study data or results, the publication or presentation must be provided to Concert for review at least 60 days in advance. If Concert needs to file a patent application prior to publication, the publication can be delayed up to 90 days from Sponsor providing notice to the investigator of such need.
Results Point of Contact
Name/Title: | Colleen E. Hamilton |
Organization: | Concert Pharmaceuticals, Inc. |
Phone: | 781-860-0045 |
EMail: | AAclinicaltrial_inquiries@concertpharma.com |
Responsible Party: | Concert Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT04797650 |
Other Study ID Numbers: |
CP543.3002 2021-000387-30 ( EudraCT Number ) |
First Submitted: | March 10, 2021 |
First Posted: | March 15, 2021 |
Results First Submitted: | June 5, 2023 |
Results First Posted: | July 3, 2023 |
Last Update Posted: | July 3, 2023 |